Prof. Dr. med. Sibylle Loibl speaks about “The speed of innovation: from gene therapies to digital evidence in clinical practice.”
As part of the F.A.Z. “Next Generation AMNOG” Capital City Dialogue, representatives from industry, politics, science, and patient advocacy discussed the future of drug evaluation in Germany.
Fifteen years after the introduction of AMNOG, key questions are taking center stage: How can a system be designed that promotes innovation, remains patient-centered, and at the same time ensures long-term reliability? In light of rapid medical progress, this dialogue is becoming increasingly important.
Prof. Dr. med. Sibylle Loibl, Managing Director of GBG Forschungs GmbH, gave a presentation on this topic and participated in the subsequent discussion on future challenges and potential solutions for the next decade of drug evaluation.
The presentation is now available on our website.
